Clinical Trial Search

Primary: Number of Participants With an Adverse Event (AE) — 4; 5; 6; 3 participants

Primary: Cmax: Maximum Observed Plasma Concentration for Febuxostat — 883.58; 1075.08; 765.89; 1456.42 nanogram per milliliter (ng/mL)

Primary: Saxagliptin Maximum Observed Concentrations (Cmax) — 26.2; 25.5 ng/mL — p=0.4950

Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2

Primary: Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States — 1020.0000; 1531.6286 ng/mL

Primary: Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ) — 1912.0; 1783.7; 448.3; 455.3 nanogram per milliliter…

Primary: Area Under the Serum Concentration Time Curve From Zero to Day 7 (AUC0-7) of Obinutuzumab on Day 1, Cycle 1 — 1458; 1750; 1647 day*micrograms per milliliter

Primary: Mean Sleep Latency Score on the Maintenance of Wakefulness Test (MWT) for Participants Taking MK-7288 Versus Placebo — 18.66; 18.62; 20.71; 10.50 Minutes

Primary: Cmax of Olaparib — 7.227; 9.081; 9.977 μg/mL

Primary: Number of Participants With Virologic Response Defined as >= 3 Log Drop in Viral Load From Baseline at Day 28 With no Evidence of Virologic Rebound During These 28 Days…

Primary: AUC 0-infinity (Area Under the Concentration-time Curve of the Cyclo in Plasma Over the Time Interval From 0 Extrapolated to Infinity) — 672; 732 ng*h/mL — p=0.0033

Primary: Number of Participants With Adverse Events — 3; 4; 10; 2 participants

Primary: To Evaluate Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC After Single Administration of 50 mg Diclofenac Sodium, With and Without Co-administration…

Primary: Number of Subjects With Drug Related Adverse Events — 5; 1; 0; 0 Participants

Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs — 9; 8…